Honasa Consumer, the parent company of popular brand Mamaearth, has officially terminated its proposed acquisition of a majority stake in Fluence Pharma. The ₹135 crore deal was called off due to the non-fulfilment of certain closing conditions outlined in the initial agreement. Despite this development, Honasa has reaffirmed its strategic commitment to entering the burgeoning nutraceuticals market.
Details of the Terminated Agreement
The acquisition, first announced in June, involved Honasa purchasing a 58% stake in the nutraceuticals startup from its existing shareholders. This secondary transaction was valued at ₹135 crore and was expected to be finalized within eight weeks. The completion was contingent upon meeting specific conditions precedent which ultimately were not satisfied.
The original agreement also included a structured plan for Honasa to acquire the remaining 42% of Fluence Pharma over the next five to seven years. This would have been executed through two additional tranches of secondary purchases. With the initial transaction now cancelled, these subsequent stake acquisitions will also not proceed as planned.
Reasoning and Strategic Implications
In a regulatory filing, Honasa Consumer stated the termination was a result of closing conditions not being met under the share purchase agreement. The company did not provide specific details regarding which particular conditions were unfulfilled. This leaves the precise reasons for the deal's collapse undisclosed to the public.
The planned merger was set to combine Fluence Pharma's patented cyclical nutrition therapy and its extensive network of over 3,000 dermatologists. Honasa intended to leverage these assets with its own significant brand-building, marketing, and distribution capabilities. This intended synergy was a core component of the acquisition's strategic value for Honasa.
Honasa's Unwavering Focus on Nutraceuticals
Despite the setback, Honasa remains resolute in its ambition to build a strong presence in the nutraceuticals sector. The company views this as its next major growth frontier, targeting an addressable market estimated at approximately ₹16,000 crore. This focus is driven by growing consumer demand for "inside-out" solutions for skin and hair health.
This strategic push is a key pillar of the company's five-year "Honasa 3.0" vision, which aims to more than double its revenue. As part of this initiative, Honasa had already incorporated a wholly owned subsidiary named Honasa Health. This entity was established to manage the end-to-end operations of its new consumer-focused nutraceuticals business.
Honasa has a track record of expanding its portfolio through strategic acquisitions, having previously bought brands like Dr. Sheth’s and BBlunt. These moves have allowed the company to enter new categories and reduce its reliance on its flagship brand, Mamaearth. The company has confirmed it will continue to evaluate both organic and inorganic growth opportunities.
Company Financials and Market Position
Fluence Pharma, founded by Amit Bhusari and dermatologist Rajendra Singh Rajput, has demonstrated strong business fundamentals. The company reported revenue of around ₹40 crore in fiscal year 2026 with an impressive EBITDA margin exceeding 20 percent. Its business model is centered on selling supplements exclusively through its professional network of dermatologists and trichologists.
Honasa Consumer itself continues to exhibit robust financial performance, lending credibility to its expansion plans. In its most recent quarterly results, the company's consolidated net profit more than doubled to ₹90.5 crore. This was achieved on the back of its highest-ever quarterly operating revenue of ₹755.9 crore.
In conclusion, the termination of the Fluence Pharma acquisition marks a notable change in Honasa Consumer's immediate execution but not its long-term strategy. The company's strong financial position and clear commitment to the nutraceuticals market suggest it will actively seek alternative paths for growth. Observers will be watching closely to see how Honasa pivots to achieve its ambitious "Honasa 3.0" goals.